Phase 2
Completed N=40
A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis
Perennial Allergic Rhinoconjunctivitis · House dust mite allergy
Source: ClinicalTrials.gov NCT00574704 ↗
Enrolled (actual)
40
Serious AEs
2.5%
Results posted
Jul 2013
Primary outcomePrimary: Conjunctival Provocation Test (CPT) With House Dust Mite Allergen Solutions. Change of Median Individual Allergen Tolerance Compared to Baseline (Factor of Increase in Allergen Concentration to Induce a Threshold CPT Score ≥ 2) — 10; 10; 10; 1 Factor of Increased Allergen Tolerance
Summary
The purpose of the study is to test the efficacy of the combination treatment AllQbG10 in patients with perennial allergic rhinoconjunctivitis due to house dust mite allergy in a double-blind, placebo-controlled setting
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Conjunctival Provocation Test (CPT) With House Dust Mite Allergen Solutions. Change of Median Individual Allergen Tolerance Compared to Baseline (Factor of Increase in Allergen Concentration to Induce a Threshold CPT Score ≥ 2) |
10; 10; 10; 1 | — |
| SECONDARY Safety and Tolerability of the Study Treatment by Collection of Adverse Events |
— | — |
Eligibility Criteria
Inclusion Criteria
- Mild to moderate perennial allergic rhinoconjunctivitis due to hypersensitization towards house dust mite allergens
Exclusion Criteria
- Clinically relevant other allergies (perennial or seasonal) that could potentially interfere with the patient's study treatment schedule or assessments
- Use of any concomitant medication that could affect the patient's study treatment response or assessment results
Data sourced from ClinicalTrials.gov (NCT00574704). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.